Electroporation for therapeutic DNA vaccination in patients
详细信息 查看全文
- 作者：Matti S?llberg ; Lars Frelin ; Gustaf Ahlén…
- 关键词：Therapeutic vaccine ; HBV ; DNA vaccine ; Electroporation ; T cell
- 刊名：Medical Microbiology and Immunology
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：204
- 期：1
- 页码：131-135
- 全文大小：853 KB
- 参考文献：1. Ulmer JB et al (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-749 in new window">CrossRef
2. Calarota S et al (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351(9112):1320-325 in new window">CrossRef
3. MacGregor RR et al (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92-00 in new window">CrossRef
4. Wang R et al (1998) Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:476-80 in new window">CrossRef
5. Neumann E, Rosenheck K (1972) Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol 10:279-90 in new window">CrossRef
6. Neumann E et al (1982) Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1:841-45
7. Mir LM et al (1991) Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27:68-2 in new window">CrossRef
8. Belehradek M et al (1993) Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 72:3694-700 in new window">CrossRef
9. Heller R (1995) Treatment of cutaneous nodules using electrochemotherapy. J Fla Med Assoc 82:147-50
10. Heller R et al (1996) Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 77:964-71 in new window">CrossRef
11. Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16:867-70 in new window">CrossRef
12. Mathiesen I (1999) Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6:508-14 in new window">CrossRef
13. Ahlen G et al (2007) In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ cells. J Immunol 179:4741-753 in new window">CrossRef
14. Luxembourg A et al (2006) Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 24:4490-493 ine.2005.08.014" target="_blank" title="It opens in new window">CrossRef
15. Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301-05 in new window">CrossRef
16. Schenten D, Medzhitov R (2011) The control of adaptive immune responses by the innate immune system. Adv Immunol 109:87-24 in new window">CrossRef
17. Bagarazzi ML (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4:155ra138 in new window">CrossRef
18. Weiland O et al (2012) Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther 21:1796-805 in new window">CrossRef
19. Keane-Myers AM et al (2014) DNA electroporation of multi-agent vaccines conferring protection against select agent challenge: TriGrid delivery system. Methods Mol Biol 1121:325-36 in (1)
Gustaf Ahlén (1)
Margaret S?llberg-Chen (1) (2)
1. Division of Clinical Microbiology, F68, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden
2. Department of Dental Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden - 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Medical Microbiology
Immunology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-1831
文摘
DNA vaccination has historically failed to raise strong immune responses in humans. Recent delivery techniques such as the gene gun and in vivo electroporation (EP)/electrotransfer (ET) have completely changed the efficiency of DNA vaccines in humans. In vivo EP exerts multiple effects that contribute to its efficiency. The two central factors are most likely the increased DNA uptake due to the transient membrane destabilization, and the local tissue damage acting as an adjuvant. To date, several studies in humans have used in vivo EP/ET to deliver DNA. Some of these results have been quite promising with strong T cell responses and/or transient effects on the viral replication. This suggests that improved strategies of in vivo EP/ET can be a future way to deliver DNA in humans.